Veristat Congratulates Agios Pharmaceuticals on the FDA Approval of TIBSOVO®
Veristat, a full service Clinical Research Organization (CRO), congratulates Agios on the recent FDA approval of TIBSOVO® (ivosidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test. TIBSOVO®, an oral, targeted inhibitor of the IDH1 enzyme, is the first and only FDA-approved therapy for patients with R/R AML and an IDH1 mutation.
Veristat is honored to have supported Agios with the preparation of the New Drug Application (NDA) for ivosidenib. We congratulate Agios on the approval of this ground-breaking therapy for patients with this life-threatening malignancy. Veristat began working with Agios on this compound five years ago, providing statistical and medical writing support for their phase I study for ivosidenib which led to the recent approval. Veristat’s support continued through the preparation of the NDA submission.
“Over the last five years, I have personally had the privilege to work with a dedicated Agios team on the Investigational New Drug (IND) application, phase I study, and NDA submission for ivosidenib,” said Barbara Balser, VMD, Executive Vice President and Chief Scientific Officer at Veristat. “I am thrilled to see TIBSOVO® receive FDA approval and look forward to seeing this therapy help improve the lives of patients with R/R AML.”
Veristat’s specialization in preparing oncology and rare disease regulatory submissions, as well as its experience with the FDA, uniquely positioned Veristat to support Agios with this program. Cancer therapies account for more than 45% and rare disease indications over 55% of the regulatory submission projects that Veristat has worked on.
“On behalf of the entire Veristat team, I applaud Agios for their focus on advancing this program to quickly bring this novel treatment to cancer patients with no other options,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “Our teams worked tirelessly to support Agios leading up to this approval and remain committed to assist Agios as they look to expand this compound into new indications and bring additional compounds into early phase trials.”
Veristat is a clinical research partner focused on supporting biopharmaceutical firms as they advance their therapies through the clinical development and regulatory submission process. Our work delivers meaningful clinical impact and our regulatory submission expertise is unrivaled in our industry. Veristat teams have worked on over 70 regulatory submission projects that have resulted in more than 40 submission approvals to date from various regulatory agencies around the world. Over the last 5 years alone, nearly 8% of new molecular entities (NMEs) approved by the FDA were supported by Veristat teams. Veristat aims is to propel even the most complex submissions to successful regulatory conclusions so that new therapies become available to improve and save lives. For more information, visit www.veristat.com.
TIBSOVO® is a registered trademark of Agios.
Gillian Dellacioppa, 508-306-6336
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
The Valence Group Advises INEOS Enterprises on Its Acquisition of Ashland’s Composites Business and BDO Facility in Germany15.11.2018 18:19 | Tiedote
The Valence Group acted as financial advisor to INEOS Enterprises on its announced acquisition of the Composites business and BDO facility in Germany of Ashland Global Holdings Inc. (“Ashland”) for $1.1 billion. The transaction is expected to complete in the first half of 2019, subject to regulatory approval and consultation processes. The Composites business is a global leader in unsaturated polyester resins, vinyl ester resins and gel coats. In addition to its wide range of gelcoats, the business also provides corrosion-resistant fiberglass reinforced plastics which provide exceptional durability, superior heat resistance, low maintenance and high performance for challenging environments. The BDO facility in Marl, Germany produces key intermediates for high performance polyesters and polyurethanes. The businesses included in the transaction comprise 20 manufacturing sites in Europe, North and South America, Asia and the Middle East, employ 1,300 people and generate combined sales of
Andersen Global Adds Tax & Legal Services in Argentina15.11.2018 17:30 | Tiedote
Andersen Global announced today it signed a Collaboration Agreement with Goldemberg Saladino Hermida Rolando & Asociados, in Buenos Aires. This is the second Andersen Global collaborating firm in the commerce hub of Buenos Aires, and the 20th location in nine different Latin American countries. For thirty years, the team at Goldemberg Saladino Hermida Rolando & Asociados has provided tax consulting and compliance, international tax planning, transfer pricing, tax and customs litigation, payroll, bookkeeping, wealth management services, financial and business consulting to high-profile private and public entities, including local, national and international corporations and non-profits, foundations and similar organizations. The firm joins the global association with over 100 personnel and eight Partners. “The addition of Goldemberg Saladino Hermida Rolando & Asociados only further strengthens an impressive roster for the Andersen name in Latin America,” said Mark Vorsatz, Andersen Glob
Axonics® Granted Seven U.S. Utility Patents Related to its Implantable Sacral Neuromodulation Technology15.11.2018 17:00 | Tiedote
Axonics Modulation Technologies, Inc., (NASDAQ: AXNX) developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunction, announced today that the United States Patent and Trademark Office has issued Axonics seven U.S. utility patents in 2018, along with numerous foreign counterparts relating to its implantable Sacral Neuromodulation technology. The U.S. patents issued range in subject matter and include coverage of the Axonics clinician programmer, patient remote control, and internal system electronics. The issued U.S. patents are: 10,029,090; 9,855,436; 10,092,762; 9,855,423; 9,895,546; 10,105,542; 9,925,381. “Axonics is committed to rapidly bringing innovative technology to market in order to serve the unmet needs of the millions of patients suffering from urinary and bowel dysfunction and the healthcare providers who serve them. We believe that the continued growth of our patent portfolio demonstrates how serious we are in
Attention Business Leaders: These Six Trends Will Impact Your 2019 Digital Transformation Journey15.11.2018 17:00 | Tiedote
Digital moonshots, apps at the edge and information enlightenment will be among the enterprise digital trends to watch in 2019, according to new predictions by DXC Technology (NYSE: DXC), the world’s leading independent, end-to-end IT services company. The company today laid out six predictions that will define the IT shifts organizations will need to think about to drive their digital strategies next year. “Business transformation is accelerating as enterprises make big bets on digital strategy to gain operational efficiencies, invent new markets, redesign customer experiences and achieve savings they can reinvest to fund a digital future,” said Dan Hushon, senior vice president and chief technology officer, DXC Technology. “Enterprise leaders should examine how these six trends will shape their digital journey so they can get it right, learn fast and execute forward in 2019.” Hushon identified six digital trends that will accelerate business transformation in 2019: 1) Enterprises go
A-Nex Launches Initial Coin Offering (ICO) Showcasing Unhackable Cryptocurrency Technology for Internet Security15.11.2018 17:00 | Tiedote
A-Nex, a cyber coin company, announces its initial coin offering (ICO) today. This innovative crypto enterprise is designed for the sale and exchange of virtual currencies, smart contracts and tokens. Non-US crypto-enthusiasts, particularly the community in Korea, will be able to start their transactions immediately. Those who wish to participate will be able to invest in a new, digital advancement that is expected to grow and to provide numerous benefits for the crypto economy. It promises to revolutionize the decentralized financial landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005017/en/ Bruce Khavar, Founder and CEO, of Cyber Advanced Technology (Photo: Business Wire) The company providing its technology, Cyber Advanced Technology (CAT), is one of the leaders of the digital scene. They have invented an unhackable cloud technology that will keep the cryptobusiness secure and well-protected. Investor’s mo
This Fall PotNetwork Holdings, Inc. Will Launch The “PotNetwork Magazine” Giving You an Insider’s Take on The Cannabis Industry15.11.2018 16:00 | Tiedote
PotNetwork Holdings’ “PotNetwork News” (www.potnetwork.com), the cannabis industry’s top outlet for financial, political, and industry news is set to launch the first edition of their all-new print magazine. PotNetwork Magazine gives the crack PotNetwork editorial team an opportunity to provide an unparalleled analysis of the untold stories of the cannabis space, while still channeling the unbiased, hard hitting style that has made PotNetwork.com such a sensation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005318/en/ PotNetwork Magazine (Photo: Business Wire) PotNetwork Magazine will explore every sector of the cannabis industry from ancillary companies all the way up to growers who directly touch the plant. It will become an indispensable resource for industry leaders and budding entrepreneurs alike. The magazine will include detailed analysis of topics including hemp products, consumption devices, investing & fin
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme